A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Spondyloarthritis
Completed · Phase 3 · NCT04169373
Conditions: Spondyloarthritis
At a glance
- Research payments reported, 2025
- $21,170
- U.S. investigators named
- 2
- Sites paid
- 1
- Planned or actual enrollment
- 734
About the trial
- Sponsor
- AbbVie
- Tested
- Upadacitinib (drug), Placebo (drug)
- Dates
- Started 2019-11-26; completion 2025-02-28
- Results posted
- Yes
This protocol includes 2 standalone studies with randomization, data collection, analysis and reporting conducted independently. The main objectives of this protocol are: * To evaluate the efficacy of upadacitinib compared with placebo on reduction of signs and symptoms in adults with active axial spondyloarthritis (axSpA) including biologic disease-modifying antirheumatic drug inadequate responders (bDMARD-IR) ankylosing spondylitis (AS) (Study 1) and non-radiographic axial spondyloarthritis (nr-axSpA) (Study 2). * To assess the safety and tolerability of upadacitinib in adults with active axSpA including bDMARD-IR AS (Study 1) and nr-axSpA (Study 2). * To evaluate the safety and tolerab…
From ClinicalTrials.gov, last updated 2026-02-24. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $21,170 in research payments for this study in 2025 (4 payments).
Products named: Rinvoq
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Kamran A. Chaudhary, MD Rheumatology · Schaumburg, IL
- Robert A. Hozman, M.D. Rheumatology · Skokie, IL
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Clinical Investigation Specialists $21,170
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.